5 September 2019 - Cigna and CVS Health are developing new programs to help employers afford gene therapies that can cost more than $2 million.
Insurers are scrambling to blunt the expense of new drugs that can carry prices of more than $2 million per treatment, offering new setups aimed at making the cost of gene therapies more manageable for employers.
Cigna announced Thursday a new program that allows employers and insurers to pay per-month fees for a service that will cover the cost of gene therapies and manage their use. CVS Health says it plans to offer a new layer of coverage specifically for gene therapies, which would handle employers’ costs above a certain threshold. Anthem said it is looking at special insurance setups to help employers protect themselves from the financial impact of the drugs.